1
Clinical Trials associated with Anti-BCMA|CD38 CAR-T (Chinese People's Liberation Army General Hospital) / Unknown statusPhase 1/2IIT Phase I/II Study to Evaluate Treatment of Relapsed or Refractory Multiple Myeloma With Dual CAR-T Cells Targeting CD38 and BCMA
CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory Multiple Myeloma,however, a subset of patients relapse due to the loss of target in tumor cells.Dual Specificity CD38 and BCMA CAR-T cells can recognize and kill the malignant cells through recognition of CD38 or BCMA. This is a phase 1/2 study designed to determine the safety of dual specificity CD38 and BCMA CAR-T cells and the feasibility of making enough to treat patients with relapsed or refractory Multiple Myeloma.
100 Clinical Results associated with Anti-BCMA|CD38 CAR-T (Chinese People's Liberation Army General Hospital)
100 Translational Medicine associated with Anti-BCMA|CD38 CAR-T (Chinese People's Liberation Army General Hospital)
100 Patents (Medical) associated with Anti-BCMA|CD38 CAR-T (Chinese People's Liberation Army General Hospital)
100 Deals associated with Anti-BCMA|CD38 CAR-T (Chinese People's Liberation Army General Hospital)